News >

Ixazomib Phase III Trial Discontinued in AL Amyloidosis

Gina Columbus @ginacolumbusonc
Published: Thursday, Jun 06, 2019

Phil Rowlands, PhD

Phil Rowlands, PhD

Ixazomib (Ninlaro) in combination with dexamethasone did not demonstrate a significant improvement in overall hematologic response compared with standard therapy in patients with relapsed/refractory systemic light-chain (AL) amyloidosis, missing one of two primary endpoints in the phase III TOURMALINE-AL1 trial and leading to discontinuation of the study.1

Ixazomib is currently approved by the FDA in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received ≥1 prior therapy.

References

  1. Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis. Takeda Pharmaceutical Company. Published June 5, 2019. https://bit.ly/2Xu2CIX. Accessed June 5, 2019.
  2. Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605. doi: 10.1182/blood-2017-03-771220.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x